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INTRODUCTION
Autoimmune cytopenia (AIC) is relatively common in
patients with chronic lymphocytic leukemia occurring
in 5-10% of patients during the course of their disease.1
Autoimmune hemolytic anemia (AIHA) constitutes the
highest prevalence (5-10%) of CLL-associated AIC
followed by idiopathic thrombocytopenic purpura (ITP)
(2-5%), pure red cell aplasia (PRCA) (<1%), and
autoimmune neutropenia (AIN) (<1%).2,3 The prevalence
of AIN, however, may in fact be higher than reported
due to a lack of awareness of the condition and difficulty
in its diagnosis. 4 Despite its rarity, autoimmune
neutropenia can be a significant clinical challenge in
patients with CLL and can increase the risk of infectious
complications. Thus, the prompt diagnosis and
resolution of CLL-associated AIN is essential to the
management of these patients.
Ibrutinib is a selective inhibitor of Bruton tyrosine kinase
and induces a durable response in patients with CLL.5
The activity of ibrutinib in CLL-associated AIC is largely
unknown as pivotal clinical trials excluded patients with
AIC. We report a case of a patient with CLL who
experienced worsening of AIN after discontinuing
ibrutinib therapy. Given its immune modulatory effects,
these findings suggest ibrutinib may have a role in
controlling AIN in patients with CLL.

CASE PRESENTATION
This is a 72 year-old female who was diagnosed with
CLL in early 2000 after presenting with progressive left
cervical lymphadenopathy. Prognostic markers of CLL
were not evaluated at the time of diagnosis. She was
treated with fludarabine and rituximab and achieved a
complete response. She continued on active surveillance
for five years until she had evidence of disease
recurrence.
She was treated with single agent rituximab in 2005 and
then rituximab-bendamustine in 2009 and achieved
complete remission. In 2012, she had evidence of
disease progression with diffuse adenopathy and a
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biopsy was performed to rule out disease transformation.
FISH studies at that time revealed trisomy 12 and 17p
deletion. The patient did not wish to undergo further
chemotherapy and instead was treated with high dose
methylprednisolone with rituximab followed by
lenalidomide. Her CLL was controlled on this regimen,
however, she developed thrombocytopenia (platelet
count of 46,000 per cubic millimeter), leg heaviness,
and fatigue from the lenalidomide and it was stopped in
June 2014. Three weeks after stopping lenalidomide,
she developed incidental neutropenia with an absolute
neutrophil count (ANC) of 900 cells/µL. Due to a lack of
constitutional symptoms, she was not treated for her
neutropenia and her counts improved spontaneously.
In September 2014, she was started on ibrutinib for
disease progression and achieved a partial response.
However, by August 2017 she noted increased pelvic
lymphadenopathy and leukocytosis consistent with
progressive disease. Genome sequencing studies
revealed the presence of a BTKI mutation (C481S)
conferring resistance to ibrutinib as well as an IGH-BCL2
rearrangement, ATM R248, and NOTCH1. Ibrutinib was
discontinued in November 2017 and venetoclax was
initiated. Subsequently, her ANC began declining which
was initially thought to be a related side effect of
venetoclax (Figure 1). However, despite multiple dose
reductions and interrupting venetoclax for 7 weeks, her
ANC remained below 500 cells/uL. The differential
diagnosis at this time included myelodysplastic
syndrome and autoimmune neutropenia. Therefore, a
bone marrow biopsy was performed which revealed
only 10% involvement with CLL and no evidence of
myelodysplasia. Moreover, there was evidence of
myeloid maturation arrest fur ther suggesting
autoimmunity as her etiology of neutropenia. She
received oral steroids and rituximab which resulted in a
rapid resolution of her neutropenia. However, due to a
decreasing ANC (Figure 1), tbo-filgastrim was added to
her regimen every 10 days. Venetoclax was restarted, in
conjunction with tbo-filgastrim, and her ANC continued
to be maintained above 1000 cells/uL. She has remained
stable on this therapeutic regimen for almost one year.

Figure 1.

DISCUSSION
We present a case of worsening AIN after stopping
ibrutinib that was successfully managed with steroids,
rituximab, and infrequent growth factor support. AIN is
relatively uncommon in patients with CLL, but its
presence should be suspected if other causes of
neutropenia are ruled out. The pathogenesis of AICs in
patients with CLL is not well understood and is possibly
related to immune dysregulation including ineffective
regulatory T-cell function. Additionally, humoral
immunity can also be impacted as CLL cells may process
cryptic antigens differently from normal B cells and thus
present a peptide for which there is no immunological
tolerance.6 Lastly, AICs in patients with CLL can also be
drug-induced (purine analogs and alkylating agents).7
The role of ibrutinib in AIN is controversial and patients
with AICs were largely excluded from pivotal ibrutinib
clinical trials. In a retrospective analysis of 301 CLL
patients treated with ibrutinib at Ohio State University
Cancer Center, six patients developed treatmentemergent AICs. However, these episodes of AIC occurred
within 6 days to 23 months after ibrutinib initiation and
thus did not appear to be temporally linked to the
therapy. Furthermore, 25% of these patients had a past
history of AICs and 7% were already receiving active
therapy for AIC at the time of ibrutinib initiation.8
In the phase 3 RESONATE-1 study, which compared
ibrutinib vs. ofatumumab in previously treated CLL/SLL
patients, ibrutinib did not precipitate recurrent AICs in
patients with CLL who had a history of autoimmune
complications.9 In fact, ibrutinib may play a therapeutic
role in the prevention and treatment of AICs in patients
with CLL.10 This was illustrated in one retrospective study

using pooled data from four clinical trials which found
that AIC therapy was discontinued in 86% of patients
after a median of 4.7 months of initiating ibrutinib. 8
Similarly, our group previously reported a case of CLL
induced ITP that was successfully controlled with
ibrutinib and rapidly flared after brief ibrutinib discontinuation. 11 This also mirrors another case reported by
Molica et al where a patient with CLL-associated AIHA
experienced exacerbation of hemolysis twice after
stopping ibrutinib.12 Conversely, some reports suggest
that ibrutinib may initially and transiently worsen AIHA in
patients with CLL, but with continued use, it may
ultimately control AICs.
Our report suggests a role for ibrutinib in controlling
CLL-associated AICs including AIN. Ibrutinib has a variety
of mechanisms which can influence the immune system
and potentially influence AICs. It inhibits interleukin-2inducible kinase (ITK), which decreases the response of
autoreactive T cells and can also modulate cytokine levels
to promote a shift from a Th-2 towards a Th-1 mediated
immune response. Additionally, ibrutinib inhibits B-cell
receptor signaling which can inhibit the ability of B cells to
respond to produce pathologic antibodies.8 Literature on
this notion is currently conflicting and further research is
needed to better elucidate the relationship between
ibrutinib, CLL, and AICs.
CLL-associated AICs, such as AIN, are common
throughout the course of disease. Steroids, immunosuppressive, or granulocyte stimulating therapy in the case
of AIN are the current standard treatment options.
Ibrutinib may be a new therapeutic option for AIN
patients with concomitant treatment indications for their
underlying CLL. This case also illustrates that some
patients may develop an AIN flare after stopping ibrutinib.
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